Search Result
Results for "
initiator
" in MedChemExpress (MCE) Product Catalog:
25
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-121320
-
|
|
Caspase
Apoptosis
|
Cancer
|
|
Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9 .
|
-
-
- HY-126573
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .
|
-
-
- HY-112484
-
|
|
Organoid
|
Cancer
|
|
RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.
|
-
-
- HY-W543743
-
|
1-Vinylpyrene
|
Others
|
Cancer
|
|
1-Ethenylpyrene (1-Vinylpyrene) is an anti-chemical carcinogen that inhibits the formation of skin tumors initiated by either DMBA (HY-W011845) or Benzo[a]pyrene (HY-107377) .
|
-
-
- HY-D1453
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Immune initiator-1 (Compound 1a) is an amino acid-modified near-infrared Aza-BODIPY photosensitizer, acts as an immune initiator for potent photodynamic research in melanoma .
|
-
-
- HY-D1452
-
|
|
Fluorescent Dye
|
Cancer
|
|
BDP-4 is an amino acid-modified near-infrared Aza-BODIPY photosensitizer, acts as an immune initiator for potent photodynamic research in melanoma .
|
-
-
- HY-W110166
-
-
-
- HY-124052
-
|
|
RSV
|
Infection
|
AZ-27 is a respiratory syncytial virus (RSV) inhibitor. AZ-27 can differentially suppress various RSV polymerase activities at the promoter, thereby inhibiting the early stages of mRNA transcription and genome replication by targeting the promoter .
|
-
-
- HY-P4808
-
|
|
Amyloid-β
Autophagy
|
Neurological Disease
|
|
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .
|
-
-
- HY-126573R
-
|
|
Others
|
Cancer
|
|
Trilaurin (Standard) is the analytical standard of Trilaurin. This product is intended for research and analytical applications. Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .
|
-
-
- HY-P4808A
-
|
|
Amyloid-β
Autophagy
|
Neurological Disease
|
|
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .
|
-
-
- HY-150042
-
|
|
YAP
|
Cardiovascular Disease
Others
|
|
TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration .
|
-
-
- HY-P1807
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Mast Cell Degranulating Peptide HR-2, a 14-membered linear peptide isolated from the venom of the giant hornet Vespa orientalis, is capable of degranulating mast cells and thus initiating histamine release .
|
-
-
- HY-124867
-
|
|
TSH Receptor
|
Endocrinology
|
|
D3-βArr is a positive allosteric modulator for thyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 by direct TSHR activation and potentiates TSH-mediated preosteoblast differentiation in vitro .
|
-
-
- HY-N12233
-
|
|
Apoptosis
MDM-2/p53
Reactive Oxygen Species
|
Cancer
|
|
Condurango glycoside A is an activator of p53. Condurango glycoside A initiates ROS generation and up-regulates p53 expression. Condurango glycoside A induces apoptosis and pre-mature senescence associated with DNA damage in HeLa cells .
|
-
-
- HY-13992
-
AP20187
Maximum Cited Publications
27 Publications Verification
B/B Homodimerizer
|
FKBP
|
Metabolic Disease
|
|
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
|
-
-
- HY-112554
-
|
|
Others
|
Others
|
|
PDM11 is a derivative of antioxidant resveratrol. PDM11 do not exhibit any significant protective effect against oxidation of linoleate micelles initiated by radiolysis-generated hydroxyl radicals. PDM11 is inactive in resveratrol activity assays .
|
-
-
- HY-P2145
-
|
EDF
|
Bacterial
|
Infection
|
|
Extracellular death factor (EDF) is the only single signaling molecule involved in Escherichia coli quorum sensing, and can initiate MAZEF-mediated cell death. Extracellular death factor significantly amplifies the endoribonucleolytic activities of both MazF and ChpBK .
|
-
-
- HY-126316
-
Zapalog
1 Publications Verification
|
FKBP
|
Others
|
|
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .
|
-
-
- HY-W087905
-
|
|
Biochemical Assay Reagents
|
Others
|
|
2,3-Dimethyl-2,3-diphenylbutane is one of the decomposition of Dicumylperoxide (DCP). Diallyl orthophthalate (DAOP) is a reactive plasticizer initiated by 2,3-dimethyl-2,3-diphenylbutane for improving polyphenylene oxide (PPO) processing .
|
-
-
- HY-119160
-
|
|
PAI-1
|
Inflammation/Immunology
Cancer
|
|
TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC50 of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .
|
-
-
- HY-167294
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167295
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167296
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167297
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167298
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167299
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167300
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167301
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167302
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167303
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167304
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167305
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167306
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167307
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167308
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167309
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167310
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167311
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167312
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167313
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167314
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG5000-Thiol can be used in drug delivery research .
|
-
-
- HY-167315
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG3000-Thiol can be used in drug delivery research .
|
-
-
- HY-167316
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG2000-Thiol can be used in drug delivery research .
|
-
-
- HY-167317
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-162386
-
|
|
Cuproptosis
|
Cancer
|
|
UM4118 is a copper ionophore that can initiate a mitochondrial-based noncanonical form of cell death known as cuproptosis. UM4118 exhibits high sensitivity in SF3B1-mutated and adverse risk acute myeloid leukemia (AML), and can be used for AML research .
|
-
-
- HY-14756
-
|
|
Thrombopoietin Receptor
|
Others
|
|
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .
|
-
-
- HY-N6641
-
|
|
Keap1-Nrf2
PPAR
|
Inflammation/Immunology
Cancer
|
|
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .
|
-
-
- HY-15888
-
|
|
BMI1
Autophagy
|
Cancer
|
|
PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .
|
-
-
- HY-115670
-
|
|
MMP
|
Inflammation/Immunology
Cancer
|
|
GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC50s of 8.0 nM and 11.5 nM, respectively . ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells .
|
-
- HY-156242
-
|
|
Paraptosis
|
Cancer
|
|
BQZ-485 is a a potent GDI2 inhibitor through the interaction with Tyr245. BQZ-485 disrupts the intrinsic GDI2-Rab1A interaction, thereby abolishing vesicular transport from the endoplasmic reticulum (ER) to the Golgi apparatus and initiating subsequent paraptosis events .
|
-
- HY-15888A
-
|
|
BMI1
Autophagy
|
Cancer
|
|
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment .
|
-
- HY-E70094
-
|
|
DNA/RNA Synthesis
|
Others
|
|
T4 UvsX Recombinase helps initiate DNA replication on a double-stranded DNA template by catalyzing synapsis between the template and a homologous DNA single strand that serves as primer. T4 UvsX Recombinase greatly amplifies the snap-back (hairpin-primed) DNA synthesis that is catalyzed by the T4 DNA polymerase holoenzyme on linear, single-stranded DNA templates .
|
-
- HY-75800
-
|
VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
|
-
- HY-106275
-
|
Fibrin-derived peptide Bβ15-42
|
Flavivirus
Dengue virus
|
Cardiovascular Disease
|
|
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .
|
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
-
- HY-143377
-
|
|
CDK
|
Cancer
|
|
Cdc7-IN-8 is a potent inhibitor of Cdc7. Cdc7 is a serine/threonine kinase which activates MCM promotion by phosphorylating the microchromosome maintenance protein (MCM protein), an important element of the DNA replication initiator. Cdc7-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021032170A1, compound 1-1/1-2) .
|
-
- HY-134928AS
-
|
A2E-d4 TFA
|
Isotope-Labeled Compounds
|
Cancer
|
|
Pyridinium bisretinoid A2E-d4 TFA is the deuterium-labeled Pyridinium bisretinoid A2E (HY-134928). Pyridinium bisretinoid A2E (A2E)is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species .
|
-
- HY-162344
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
Ir-CA is an antitumor agent. Ir-CA can accumulate in mitochondria and induces mitochondria dysfunction. Ir-CA induces apoptosis and autophagy. Ir-CA initiates mitophagy and cell cycle arrest to kill Cisplatin (HY-17394)-resistant A549R cells. Ir-CA can effectively inhibit metastasis by inhibiting MMP-2/MMP-9 .
|
-
- HY-15424
-
|
NSC 113939; 5-ITu
|
Adenosine Kinase
|
Cancer
|
|
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
|
-
- HY-134928
-
|
A2E
|
Apoptosis
Autophagy
Reactive Oxygen Species
|
Cancer
|
|
Pyridinium bisretinoid A2E (A2E) is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E can be used in the study of retinal degenerative diseases .
|
-
- HY-19541A
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .
|
-
- HY-N10481
-
|
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
|
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC50 of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio .
|
-
- HY-W011338
-
|
|
Aryl Hydrocarbon Receptor
|
Cancer
|
|
Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs) .
|
-
- HY-134928A
-
|
A2E TFA
|
Apoptosis
Autophagy
Reactive Oxygen Species
|
Cancer
|
|
Pyridinium bisretinoid A2E (A2E) TFA is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E TFA is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E TFA mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E TFA can be used in the study of retinal degenerative diseases .
|
-
- HY-44076
-
|
Lithium phenyl-2,4,6-trimethylbenzoylphosphinate
|
Biochemical Assay Reagents
|
Others
Cancer
|
|
LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) is a free radical initiator. The free radicals produced by LAP under bioprinting conditions are potentially cytotoxic and mutagenic. In addition, the concentration of LAP affects the mechanical strength of 3D printed scaffolds. Generally, the concentration range of LAP used for curing is 0.05%-1%. The elastic modulus produced at a concentration of 0.1% is the highest, with enhanced mechanical properties and excellent biocompatibility .
|
-
- HY-B1218
-
|
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
|
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-131721
-
|
|
Others
|
Others
|
|
14,15-EET-SI is a sulfonimide (SI) analog metabolized from 14,15-EET, which is also an effective mitogen. 14,15-EET-SI can stimulate the incorporation of [3H] thymidine, activate pp60c-src and initiate the tyrosine kinase cascade, mediating their mitotic effects. Additionally, 14,15-EET-SI can increase cell proliferation as well as the expression of c-fos and egr-1 mRNA .
|
-
- HY-B1218R
-
|
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
|
Sulfaphenazole (Standard) is the analytical standard of Sulfaphenazole. This product is intended for research and analytical applications. Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-158028
-
|
|
Influenza Virus
|
Infection
|
|
PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .
|
-
- HY-W011338S
-
|
|
Aryl Hydrocarbon Receptor
|
Cancer
|
|
Benzyl butyl phthalate-d4 is the deuterium labeled Benzyl butyl phthalate[1]. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs)[2][3][4].
|
-
- HY-W011338R
-
|
|
Aryl Hydrocarbon Receptor
|
Cancer
|
|
Benzyl butyl phthalate (Standard) is the analytical standard of Benzyl butyl phthalate. This product is intended for research and analytical applications. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs) .
|
-
- HY-114571
-
|
cis-VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis . cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-149918
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Antiproliferative agent-23 is a microtubule-destabilizing agent (MDA) and efficiently disturbes the tubulin-microtubule system. Antiproliferative agent-23 induces apoptosis via a mitochondrion-dependent pathway by downregulating the Bcl-2 protein, upregulating Bax and Cyt c proteins, and activating the caspase cascade. Antiproliferative agent-23 initiates reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin resistant cancer cell line) via the PERK/ATF4/CHOP signaling pathway. Antiproliferative agent-23 has anti-tumor activity .
|
-
- HY-158684
-
|
|
PROTACs
MDM-2/p53
|
Cancer
|
|
YX-02-030M is a PROTAC MDM2 degrader. YX-02-030M inhibits MDM2-p53 binding and VHL-HIF1α binding with IC50s of 63 nM and 1.35 μM respectively. YX-02-030M binds MDM2 and recruits the VHL E3 ubiquitin ligase to initiate MDM2 degradation, and effectively kills p53 mutant or deleted Triple-negative breast cancers (TNBC) cells. (Blue: VHL ligand; Black: linker; Pink: MDM2 inhibitor) .
|
-
- HY-E70290
-
|
GALNT1
|
Endogenous Metabolite
β-catenin
Wnt
|
Cancer
|
|
N-Acetylgalactosaminyltransferase 1 (GALNT1) is a glycosyltransferase that initiates mucin-type O-glycosylation by transferring α-GalNAc from UDP-GalNAc to serine (Ser) or threonine (Thr) residues in proteins. Overexpression of N-Acetylgalactosaminyltransferase 1 in gastric cancer can promote abnormal O-glycosylation of CD44, thereby activating the Wnt/β-catenin signaling pathway and regulating the malignant behavior of gastric cancer cells. Additionally, N-Acetylgalactosaminyltransferase 1 plays a crucial role in cancer growth and metastasis by modifying the O-glycosylation of various glycoproteins, such as mucin (MUC1), osteopontin (OPN), matrix metalloproteinase-14 (MMP14), and integrin α3 .
|
-
- HY-100315
-
|
Tyrosine kinase-IN-1
|
VEGFR
PDGFR
FGFR
|
Cardiovascular Disease
|
|
Kinase Assay: Kinase Inhibition Assays Kinase activities of KDR and PDGFRα are measured as the percent of ATP consumed following the kinase reaction using luciferaseluciferin-coupled chemiluminescence. Kinase reactions are initiated by combining test compound (XL 999), ATP, kinases and substrates in a 20 mL volume using 384-well microtiter plates. For KDR, the final reaction mixture contained 3 mM ATP, 1.6 mM poly(Glu, Tyr) 4:1 and 1.5 nM KDR of residues D807-V1356 with an N-terminal GST tag. For PDGFRα, the final reaction mixture contained 2 mM ATP, 10 mM MBP and 14 nM PDGFRα of residues Q551-L1089 with an N-terminal GST tag. The reaction mixture is incubated at room temperature for 4 h (KDR) or 2 h PDGFRα before a 20 mL aliquot of Kinase Glo is added and luminescence signal is measured using a Victor2 plate reader. Total ATP consumption is limited below 50% .
|
-
- HY-N0469R
-
|
|
Endogenous Metabolite
Virus Protease
HSV
|
Infection
Metabolic Disease
Inflammation/Immunology
|
L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation .
IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity .
In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model .
L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
|
-
-
-
HY-L144
-
|
|
636 compounds
|
|
Normal mitochondrial function is critical for maintaining cellular homeostasis because mitochondria produce ATP and are the major intracellular source of free radicals. Cellular dysfunctions induced by intracellular or extracellular insults converge on mitochondria and induce a sudden increase in permeability on the inner mitochondrial membrane, the so-called mitochondrial membrane permeability transition (MMPT). MMPT is caused by the opening of pores in the inner mitochondrial membrane, matrix swelling, and outer membrane rupture. The MMPT is an endpoint to initiate cell death because the pore opening together with the release of mitochondrial cytochrome c activates the apoptotic pathway of caspases.
The normal operation of mitochondrial function is important for maintaining normal cell death and treatment of mitochondrial diseases. MCE offers a unique collection of 636 compounds with identified and potential mitochondrial protective activity. MCE Mitochondrial Protection Compound Library is critical for drug discovery and development.
|
| Cat. No. |
Product Name |
Type |
-
- HY-167294
-
|
|
Drug Delivery
|
|
PLLA5000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167295
-
|
|
Drug Delivery
|
|
PLLA5000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167296
-
|
|
Drug Delivery
|
|
PLLA5000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167297
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167298
-
|
|
Drug Delivery
|
|
PLLA4000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167299
-
|
|
Drug Delivery
|
|
PLLA4000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167300
-
|
|
Drug Delivery
|
|
PLLA4000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167301
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167302
-
|
|
Drug Delivery
|
|
PLLA3000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167303
-
|
|
Drug Delivery
|
|
PLLA3000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167304
-
|
|
Drug Delivery
|
|
PLLA3000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167305
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167306
-
|
|
Drug Delivery
|
|
PLLA2000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167307
-
|
|
Drug Delivery
|
|
PLLA2000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167308
-
|
|
Drug Delivery
|
|
PLLA2000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167309
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167310
-
|
|
Drug Delivery
|
|
PLLA1000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167311
-
|
|
Drug Delivery
|
|
PLLA1000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167312
-
|
|
Drug Delivery
|
|
PLLA1000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167313
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167314
-
|
|
Drug Delivery
|
|
PLLA10000-PEG5000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-167315
-
|
|
Drug Delivery
|
|
PLLA10000-PEG3000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG3000-Thiol can be used in drug delivery research .
|
-
- HY-167316
-
|
|
Drug Delivery
|
|
PLLA10000-PEG2000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-167317
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-44076
-
|
Lithium phenyl-2,4,6-trimethylbenzoylphosphinate
|
3D Bioprinting
|
|
LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) is a free radical initiator. The free radicals produced by LAP under bioprinting conditions are potentially cytotoxic and mutagenic. In addition, the concentration of LAP affects the mechanical strength of 3D printed scaffolds. Generally, the concentration range of LAP used for curing is 0.05%-1%. The elastic modulus produced at a concentration of 0.1% is the highest, with enhanced mechanical properties and excellent biocompatibility .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W015987
-
|
Fmoc-NH2
|
Peptides
|
Others
|
|
9-Fluorenylmethyl carbamate (Fmoc-NH2) is an amide compound with an Fmoc protecting group, which can be used as a photobase initiator to prepare organosilane-based proton exchange membranes .
|
-
- HY-P4808A
-
|
|
Amyloid-β
Autophagy
|
Neurological Disease
|
|
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .
|
-
- HY-P4808
-
|
|
Amyloid-β
Autophagy
|
Neurological Disease
|
|
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .
|
-
- HY-P1807
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Mast Cell Degranulating Peptide HR-2, a 14-membered linear peptide isolated from the venom of the giant hornet Vespa orientalis, is capable of degranulating mast cells and thus initiating histamine release .
|
-
- HY-P2145
-
|
EDF
|
Bacterial
|
Infection
|
|
Extracellular death factor (EDF) is the only single signaling molecule involved in Escherichia coli quorum sensing, and can initiate MAZEF-mediated cell death. Extracellular death factor significantly amplifies the endoribonucleolytic activities of both MazF and ChpBK .
|
-
- HY-106275
-
|
Fibrin-derived peptide Bβ15-42
|
Flavivirus
Dengue virus
|
Cardiovascular Disease
|
|
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .
|
-
- HY-P5528
-
|
|
Peptides
|
Others
|
|
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
-
- HY-P99636
-
|
ABX-CBL
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis. Gavilimomab can be used for the research of graft-versus-host disease (GVHD) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N12233
-
-
-
- HY-N6641
-
-
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
Classification of Application Fields
Disease Research Fields
Cancer
|
TNF Receptor
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
-
-
- HY-44076
-
|
Lithium phenyl-2,4,6-trimethylbenzoylphosphinate
|
Classification of Application Fields
Disease Research Fields
Cancer
|
Biochemical Assay Reagents
|
|
LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) is a free radical initiator. The free radicals produced by LAP under bioprinting conditions are potentially cytotoxic and mutagenic. In addition, the concentration of LAP affects the mechanical strength of 3D printed scaffolds. Generally, the concentration range of LAP used for curing is 0.05%-1%. The elastic modulus produced at a concentration of 0.1% is the highest, with enhanced mechanical properties and excellent biocompatibility .
|
-
-
- HY-126573R
-
-
-
- HY-N10481
-
-
-
- HY-N0469R
-
|
|
Structural Classification
Microorganisms
Source classification
Disease markers
Endocrine diseases
Amino acids
Nervous System Disorder
Endogenous metabolite
|
Endogenous Metabolite
Virus Protease
HSV
|
L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation .
IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity .
In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model .
L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-134928AS
-
|
|
|
Pyridinium bisretinoid A2E-d4 TFA is the deuterium-labeled Pyridinium bisretinoid A2E (HY-134928). Pyridinium bisretinoid A2E (A2E)is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species .
|
-
-
- HY-W011338S
-
|
|
|
Benzyl butyl phthalate-d4 is the deuterium labeled Benzyl butyl phthalate[1]. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs)[2][3][4].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-126573
-
|
|
|
Fillers
|
|
Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
